<p>The Blood Biomarkers of Thyroid Cancer</p>

Abstract

Introduction: With the gradual increase in the incidence of thyroid cancer, people's attention to thyroid cancer has also gradually increased. Although the prognosis of thyroid cancer is rather mild compared to other cancers, it will still bring a heavy psychological burden on people who have been diagnosed. At present, the diagnosis of thyroid cancer mainly depends on ultrasound and percutaneous fine needle aspiration (pFNA). Due to the unsatisfactory accuracy of the diagnosis methods we use now, there are still some thyroid nodules that cannot be clearly diagnosed before surgery. Methods: In this article, we have searched for relevant research on blood markers of thyroid cancer in the past five years and categoried them into four groups. Discussion: Though we have not found a biomarker which can diagnose thyroid cancer both sensitively and specifically, we do found many substances that are related to it, and have the potential to recognize it and help the diagnosis. And perhaps combined models can do it better.

WITHDRAWN: Association between XRCC3 rs861539(Thr241Met) polymorphism and thyroid cancer risk (a Meta-analysis)

“…The incidence of thyroid cancer has been increasing rapidly in recent years, and the largest increase in incidence of all cancers was seen for thyroid cancer in China [2] . The reason might due to the rapid development of imaging detection technologies and increasing awareness of people's health [3] , especially considering that thyroid cancer mortality remained stable at a rate of approximately 0.5 cases per 100000 persons [4] . Thyroid cancers are divided into four main sub-types(papillary, follicular, medullary, and undifferentiated cancers) [5] .To date, the mechanism of thyroid carcinogenesis remains incompletely understood, and the only well-established risk factor for thyroid cancer might be exposure to ionizing radiation [6] .…”

Elemental analysis by Metallobalance provides a complementary support layer over existing blood biochemistry panel-based cancer risk assessment

“…Some of the less common cancer types such as thyroid and endometrial cancers also had sufficiently large enough effect sizes for a similar conclusion. Typically, thyroid cancer relied on ultrasound and percutaneous fine needle aspiration for testing (Wang et al, 2020); at the same time, endometrial cancer would require an extensive panel of protein markers, e.g., MUC16, TP53, PTEN and CDH1 (Coll-de la Rubia et al, 2020), all of which in various degrees (and often conflictingly) had also been implicated in other types of cancer. In comparison, a single panel of MB should be able to predict discernible profiles that indicated potential risks prior to more invasive testing methods.…”

Nanoparticles: Promising Auxiliary Agents for Diagnosis and Therapy of Thyroid Cancers

“…Their use in monitoring of TC is more important because the search for specific biomarkers so far has not been successful. Markers related to metabolism, thyroid function, and tumor phenotype have been identified but the majority were general cancer markers [85]. BRAF V600 and calcitonin levels have a role in the treatment strategy (Figure 1) but for other hormones a lack of clear cut-off values presented the greatest problem.…”